Please ensure Javascript is enabled for purposes of website accessibility

Up 95%! No Anchor Holding Amarin Down

By Brian Orelli, PhD - Updated Apr 6, 2017 at 10:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The second phase 3 trial of AMR101 deemed a success.

There's nothing fishy about Amarin's (Nasdaq: AMRN) latest results on AMR101 -- besides the fact that the drug is made of fish oil, of course.

In its second phase 3 trial, dubbed Anchor, AMR101 was able to reduce triglycerides by a placebo-adjusted 21.5% at the higher dose and 10.1% at the lower one. The drug also lowered bad cholesterol levels by 6.2% versus placebo at the higher dose, which is rather impressive considering the patients were already taking statins such as Pfizer's (NYSE: PFE) Lipitor, AstraZeneca's (NYSE: AZN) Crestor, and Merck's (NYSE: MRK) Zocor.

A slight reduction in bad cholesterol levels was also seen at the lower dose, but it wasn't statistically significant. The lower dose is likely still approvable, though, since the main point of the medication is to lower triglyceride levels. The fact that it doesn't raise bad cholesterol levels -- like GlaxoSmithKline's (NYSE: GSK) fish oil drug Lovaza does -- should be good enough.

The Anchor trial results were actually more important than the previous Marine phase 3 trial because the potential population is about 10 times greater. Marine tested patients with extremely high triglycerides, while Anchor tested patients with mixed triglyceride levels.

Even after the run-up today, Amarin doesn't look overvalued. A market cap of $1.8 billion isn't all that expensive when you consider that Lovaza brought in more than $800 million last year and that a lot more patients should be able to take AMR101.

At this point, the only thing anchoring down Amarin down is time. The company is shooting for a third-quarter filing with the Food and Drug Administration, so it won't get an approval and start generating revenue until next year.

That is, of course, if a big pharma doesn't buy it first.

Interested in up-and-coming technology? Click here to get the Fool's free report, "The Only Stock You Need To Profit From the NEW Technology Revolution."

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.84 (-4.17%) $0.08
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$91.87 (-2.69%) $-2.54
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$65.88 (-0.95%) $0.63
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.57 (-2.52%) $-1.31
GSK Stock Quote
GSK
GSK
$43.33 (-0.85%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.